The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1

Francesca Cervi  
Epilepsy Center- ASST Santi Paolo Carlo - Milano - Italy

Veronica Saletti  
Fondazione IRCCS Istituto Neurologico Carlo Besta

Katherine Turner  
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo

Angela Peron (✉️ angela.peron@unimi.it)  
Universita degli Studi di Milano  https://orcid.org/0000-0002-1769-6548

Sara Bulgheroni  
Fondazione IRCCS Istituto Neurologico Carlo Besta

Matilde Taddei  
Fondazione IRCCS Istituto Neurologico Carlo Besta

Francesca La Briola  
Epilepsy Center- ASST Santi Paolo Carlo Milano

Maria Paola Canevini  
Universita degli Studi di Milano Facolta di Medicina e Chirurgia

Aglaia Vignoli  
Universita degli Studi di Milano Facolta di Medicina e Chirurgia

Research

Keywords: Tuberous Sclerosis Complex, TSC, Neurofibromatosis 1, NF1, TAND, TAND-Checklist, neuropsychiatric, children

Posted Date: January 7th, 2020

DOI: https://doi.org/10.21203/rs.2.20217/v1

License: ☑️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published on September 7th, 2020. See the published version at https://doi.org/10.1186/s13023-020-01488-4.
Abstract

Background: Tuberous Sclerosis Complex (TSC) and Neurofibromatosis type 1 (NF1) are neurocutaneous disorders commonly characterized by neuropsychiatric comorbidities. The TAND (Tuberous Sclerosis Associated Neuropsychiatric Disorders) Checklist is currently used to quickly screen for behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations in patients with TSC. We administered the authorized Italian version of the TAND Checklist to 42 TSC patients and to 42 age- and sex-matched NF1 patients, for a total of 84 individuals, aged 4-20 years. Aims of this study: - to test the overall usability of the TAND Checklist in NF1, -to compare the results between children and adolescents with TSC and NF1 and –to assess whether neuropsychiatric manifestations change in relation to the severity of their phenotype.

Results: TSC cohort: 35.6% had Intellectual Disability (ID), 11.9% Specific Learning Disorders (SLD), 50.0% Attention Deficit Hyperactivity Disorder (ADHD) and 16.6% anxious/mood disorder. 33.3% had formal diagnosis of Autistic Spectrum Disorder (ASD). Paying attention and concentrating (61.9%), impulsivity (54.8%), temper tantrums (54.8%), anxiety (45.2%), overactivity/hyperactivity (40.5%), aggressive outburst (40.5%), absent or delayed onset of language (40.5%), repetitive behaviors (35.7%), academic difficulties (> 40%), deficits in attention (61.9%) and executive skills (50.0%) were the most commonly reported problems. NF1 cohort: 9.5% had ID, 21.4% SLD, 46.6% ADHD, and 33.3% anxious/mood disorder. No one had a diagnosis of ASD. Commonly reported issues were paying attention and concentrating (59.5%), impulsivity (52.4%), anxiety (50.0%), overactivity/hyperactivity (38.1%), temper tantrums (38.1%), academic difficulties (> 40%), deficits in attention (59.5%), and executive skills (38.1%). Neuropsychiatric features in TSC vs NF1: Aggressive outburst and ASD features were reported significantly more frequently in TSC than in NF1.

Conclusion: The TAND Checklist used for TSC is acceptable and feasible to complete in a clinical setting, and is able to detect the complexity of neuropsychiatric involvement in NF1 as well. NF1 is mainly characterized by an ADHD profile, anxiety problems and SLD, while ASD features are strongly associated with TSC. In conclusion, the TAND-Checklist is a useful and reliable screening tool, in both TSC and NF1.

Background

Tuberous Sclerosis Complex (TSC) and Neurofibromatosis type 1 (NF1) are the two most common neurocutaneous diseases, with an incidence of 1 in 6,000 and 1 in 3,000 new live births worldwide, respectively (1)(2).

Both are typically diagnosed in early childhood or adolescence, and are lifelong, complex, multisystem and tumor-prone disorders. A wide variety of tissues and organ systems are affected, with large inter and intra-familial clinical variability and age-dependent manifestations (1)(2)(3). Clinical criteria are used to make the diagnosis of TSC and NF1, and can be complemented by molecular testing of the TSC1/TSC2 and NF1 genes, respectively (2)(4). Although characterized by distinctive clinical manifestations, TSC and NF1 share some common characteristics, especially at the neuropsychiatric level.

The most common manifestations in TSC are benign tumors affecting the skin, brain, kidneys, lungs, and heart with possible subsequent organ dysfunction as the normal parenchyma is replaced by a variety of cell types.
The prominent neurological issues are subependymal giant cell astrocytomas (SEGAs) and epileptic seizures. Epilepsy in TSC remains a major challenge, with more than 60% of the patients having drug refractory seizures (5). Neurodevelopmental disorders are common: About 50% of affected individuals have normal cognitive function, and the remaining exhibit intellectual disability (ID) of various degrees (6); at least 30% of school-aged children with TSC are at risk of academic difficulties (7); almost 50% of the patients have autism spectrum disorder (ASD) and/or attention-deficit–hyperactivity disorder (ADHD) (8)(9); anxiety and depressive disorders are often identified from early adolescence into adulthood.

Manifestations of NF1 include café-au-lait (CAL) macules, skin-fold freckling (also known as Crowe's sign), Lisch nodules, cutaneous, subcutaneous and plexiform neurofibromas causing disfigurement and compression of adjacent structures, optic pathway gliomas, skeletal abnormalities, and characteristic malignancies. Additionally, children are prone to cognitive, learning and behavioural disorders (10)(11). In particular, cognitive deficits include a generalized downshifting IQ with cognitive delay in about 4–8% of the patients (4), impairment in visuo-spatial skills in the majority of NF1 children (12)(13), in specific academic domains of reading, spelling, and mathematics in up to 75% (14)(15), and attention problems including ADHD in 60% (16) (17) (18). Difficulties in social functioning with increased rates of ASD are seen in 11% of the patients (19), and mood/anxiety disorders (20) encompassing anxiety, depression, social withdrawal, and somatic complaints have been reported (21).

Patients with TSC and NF1 are followed with disease-specific check-ups to detect medical complication, in order to set up prompt therapeutic interventions. Neuropsychiatric difficulties are common and have a significant impact on the patients’ and families’ quality of life, but are rarely assessed and treated.

In TSC the term TAND (Tuberous Sclerosis Associated Neuropsychiatric Disorders) is used to capture the multidimensional biopsychosocial difficulties of the disease (22). A specific TAND-Checklist has been developed to assess Behavioral, Psychiatric, Intellectual, Academic, Neuropsychological and Psychosocial areas (23). The purpose of the checklist is to be an easy-to-use, short and accessible tool for every health-care professional in order to assess the neuropsychiatric involvement and to identify patients needing next-step evaluation and treatment (24).

To date, no psychosocial disease-specific screening tool has been developed to assess NF1 patients (25). In addition, available recommendations for the diagnosis and clinical management of these aspects have been only recently delineated (26).

Since behavioral, psychiatric, intellectual, academic, neuropsychological and psychosocial areas can be impaired also in NF1 patients, we hypothesized that the TAND checklist could be useful for screening of neuropsychiatric needs in this population as well and be more broadly applied also to NF1. We therefore administered the TAND checklist in two homogeneous cohorts of patients with TSC and NF1, and compared the neuropsychiatric manifestations in relation to the severity of their phenotype.

**Results**

**Neuropsychiatric manifestations in the TSC and NF1 groups according to disease severity**
Tables 1 and 2 show the descriptive results of the TAND Checklist in the TSC and NF1 cohorts and relative subgroups according to the disease severity.
Table 1
Results of the TAND checklist in the TSC cohort

| TAND Features                              | NO EPILEPSY (n = 13) (30.9%) | Not active EPILEPSY (n = 16) (38.1%) | Active EPILEPSY (n = 13) (30.9%) | $X^2$ | p value |
|--------------------------------------------|------------------------------|------------------------------------|---------------------------------|-------|---------|
| Behavioral level                           |                              |                                    |                                 |       |         |
| Anxiety                                    | 7 (53.8)                     | 7 (43.8)                           | 5 (38.5)                        | 0.644 | 0.725   |
| Depressed mood                             | 1 (7.7)                      | 5 (31.3)                           | 0 (0.0)                         | 6.389 | 0.041   |
| Extreme shyness                            | 1 (7.7)                      | 5 (31.3)                           | 2 (15.4)                        | 1.592 | 0.451   |
| Mood swings                                | 2 (15.4)                     | 5 (31.3)                           | 3 (23.1)                        | 1.001 | 0.606   |
| Aggressive outbursts                       | 3 (23.1)                     | 7 (43.8)                           | 7 (53.8)                        | 2.669 | 0.263   |
| Temper tantrums                            | 6 (46.2)                     | 10 (62.5)                          | 7 (53.8)                        | 0.780 | 0.677   |
| Self-injury                                | 0 (0.0)                      | 3 (18.8)                           | 2 (15.4)                        | 2.622 | 0.270   |
| Absent or delayed onset of language        | 2 (15.4)                     | 7 (43.8)                           | 8 (61.5)                        | 5.862 | 0.050   |
| Repetitive language                        | 0 (0.0)                      | 5 (31.3)                           | 6 (46.2)                        | 7.505 | 0.023   |
| Poor eye contact                           | 0 (0.0)                      | 4 (25.0)                           | 4 (30.8)                        | 4.585 | 0.101   |
| Difficult relationship with peers          | 0 (0.0)                      | 7 (43.8)                           | 5 (38.5)                        | 7.629 | 0.022   |
| Repetitive behaviors                       | 2 (15.4)                     | 4 (25.0)                           | 9 (69.2)                        | 9.501 | 0.009   |
| Rigidity                                   | 4 (30.8)                     | 5 (31.3)                           | 4 (30.8)                        | 0.001 | 0.999   |
| Overactivity/hyperactivity                 | 5 (38.5)                     | 6 (37.5)                           | 6 (46.2)                        | 0.255 | 0.880   |
| Difficulty paying attention or concentrating | 5 (38.5)                 | 12 (75.0)                          | 9 (69.2)                        | 4.489 | 0.106   |
| Restlessness                               | 2 (15.4)                     | 4 (25.0)                           | 4 (30.8)                        | 1.001 | 0.606   |
| Impulsivity                                | 4 (30.8)                     | 9 (56.3)                           | 10 (76.9)                       | 5.612 | 0.060   |
| Difficulties with eating                   | 3 (23.1)                     | 5 (31.3)                           | 5 (31.3)                        | 0.721 | 0.697   |
| Sleep difficulties                         | 2 (15.4)                     | 5 (31.3)                           | 6 (46.2)                        | 2.880 | 0.237   |
| Scholastic level                           |                              |                                    |                                 |       |         |
| Reading                                    | 6 (46.2)                     | 6 (37.5)                           | 9 (69.2)                        | 7.008 | 0.135   |
| Writing                                    | 6 (46.2)                     | 8 (50.0)                           | 9 (69.2)                        | 5.663 | 0.226   |
| Spelling                                   | 2 (15.4)                     | 6 (37.5)                           | 11 (84.6)                       | 13.200| 0.001   |
| TAND Features                  | NO EPILEPSY (n = 13) (30.9%) | Not active EPILEPSY (n = 16) (38.1%) | Active EPILEPSY (n = 13) (30.9%) | $\chi^2$ | p value |
|-------------------------------|-----------------------------|--------------------------------------|----------------------------------|---------|---------|
| Mathematics                   | 7 (53.8)                    | 8 (50.0)                             | 11 (84.6)                       | 9.609   | 0.048   |
| Neuropsychological level      |                             |                                      |                                  |         |         |
| Memory                        | 3 (23.1)                    | 4 (25.0)                             | 4 (30.8)                        | 0.218   | 0.897   |
| Attention                     | 5 (38.5)                    | 11 (68.8)                            | 10 (76.9)                       | 4.591   | 0.101   |
| Dual-tasking                  | 4 (30.8)                    | 10 (62.5)                            | 10 (76.9)                       | 5.957   | 0.050   |
| Visuo-spatial tasks           | 1 (7.7)                     | 1 (6.3)                              | 6 (46.2)                        | 8.981   | 0.011   |
| Executive skills              | 3 (23.1)                    | 9 (56.3)                             | 9 (69.2)                        | 5.942   | 0.050   |
| Getting disoriented           | 1 (7.7)                     | 4 (25.0)                             | 7 (53.8)                        | 6.946   | 0.031   |
| Psychosocial level            |                             |                                      |                                  |         |         |
| Low self-esteem               | 2 (15.4)                    | 7 (43.8)                             | 2 (15.4)                        | 4.123   | 0.127   |
| Very high levels of stress in families | 3 (23.1) | 8 (50.0) | 5 (38.5) | 2.206 | 0.332   |
| Very high levels of stress between parents | 5 (38.5) | 8 (50.0) | 5 (38.5) | 0.538 | 0.764   |
Table 2
Results of the TAND checklist applied to the NF1 Cohort, based on clinical severity

| Neuropsychiatric manifestations                  | General Severity NF1 (Riccardi) |              |              |        |
|--------------------------------------------------|---------------------------------|--------------|--------------|--------|
|                                                  | MINIMAL (n = 19) (45.2%)        | MILD (n = 15) (35.7%) | MODERATE SEVERE (n = 8) (19.1%) | X²    | p value |
|                                                  | n (%)                          | n (%)        | n (%)        |       |
| Behavioral level                                 |                                 |              |              |       |
| Anxiety                                          | 9 (47.4)                       | 9 (60.0)     | 3 (37.5)     | 1.153 | 0.562   |
| Depressed mood                                   | 3 (15.8)                       | 4 (26.7)     | 2 (25.0)     | 0.664 | 0.718   |
| Extreme shyness                                  | 4 (21.1)                       | 3 (20.0)     | 0 (0.0)      | 1.983 | 0.371   |
| Mood swings                                      | 5 (26.3)                       | 5 (33.3)     | 1 (12.5)     | 1.172 | 0.557   |
| Aggressive outbursts                             | 4 (21.1)                       | 3 (20.0)     | 1 (12.5)     | 0.281 | 0.869   |
| Temper tantrums                                  | 9 (47.4)                       | 3 (20.0)     | 4 (50.0)     | 3.256 | 0.196   |
| Self-injury                                      | 1 (5.3)                        | 0 (0.0)      | 0 (0.0)      | 1.240 | 0.538   |
| Absent or delayed onset of language             | 3 (15.8)                       | 3 (20.0)     | 0 (0.0)      | 1.768 | 0.413   |
| Repetitive language                              | 3 (15.8)                       | 1 (6.7)      | 0 (0.0)      | 1.850 | 0.397   |
| Poor eye contact                                 | 2 (10.5)                       | 0 (0.0)      | 0 (0.0)      | 2.542 | 0.281   |
| Difficult relationship with peers                | 3 (15.8)                       | 3 (20.0)     | 0 (0.0)      | 1.768 | 0.413   |
| Repetitive behaviors                             | 1 (5.3)                        | 1 (6.7)      | 1 (12.5)     | 0.452 | 0.798   |
| Rigidity                                         | 4 (21.1)                       | 4 (26.7)     | 3 (37.5)     | 0.791 | 0.673   |
| Overactivity/hyperactivity                       | 8 (42.1)                       | 6 (40.0)     | 2 (25.0)     | 0.734 | 0.693   |
| Difficulty paying attention or concentrating     | 14 (73.7)                      | 6 (40.0)     | 5 (62.5)     | 3.984 | 0.136   |
| Restlessness                                     | 4 (21.1)                       | 4 (26.7)     | 0 (0.0)      | 2.497 | 0.287   |
| Impulsivity                                      | 12 (63.2)                      | 8 (53.3)     | 2 (25.0)     | 3.295 | 0.193   |
| Difficulties with eating                         | 6 (31.6)                       | 4 (26.7)     | 3 (37.5)     | 0.293 | 0.864   |
| Sleep difficulties                               | 8 (42.1)                       | 3 (20.0)     | 1 (12.5)     | 3.258 | 0.196   |
| Scholastic level                                 |                                 |              |              |       |
| Reading                                          | 7 (36.8)                       | 6 (40.0)     | 1 (12.5)     | 2.713 | 0.607   |
| Writing                                          | 12 (63.2)                      | 4 (26.7)     | 3 (37.5)     | 4.810 | 0.307   |
The TSC subgroups were composed of 13/42 (30.9%) individuals with no epilepsy, 16/42 (38.1%) with epilepsy that was not active at the time of the study, and 13/42 (30.9%) with active epilepsy.

The NF1 subgroups were composed of 19/42 (45.2%) patients with minimal disease, 15/42 (35.7%) with mild disease, and 8/42 (19.1%) with moderate/severe disease based on the modified Riccardi scale.

The TANDs that statistically worsened with the epilepsy burden were: depressed mood, absent or delayed onset of language, repetitive language, difficulties in relationship with peers, repetitive behaviors, spelling, mathematics, dual-tasking, visuo-spatial tasks, executive skills, and getting disoriented. The items that remained constantly highly reported with no statistical difference were: anxiety (53.8% – 43.8% – 38.5%), temper tantrums (46.2% – 62.5% – 53.8%), rigidity (30.8% – 31.3% – 30.8%), overactivity/hyperactivity (38.5% – 37.5% – 46.2%), difficulties in reading (46.2% – 37.5% – 69.2%) and writing (46.2% – 50.0% – 69.2%).

Regarding the NF1 severity subgroups, no statistically significant differences were noted for any of the items in the checklist. The most common behavioral problems were anxiety (47.4% – 60.0% – 37.5%), overactivity/hyperactivity (42.1% – 40.0% – 25.0%), temper tantrums (47.4% – 20.0% – 50.0%), difficulties...
paying attention or concentrating (73.7% – 40.0% – 62.5%), impulsivity (63.2% – 53.3% – 25.0%), sleep difficulties (42.1% – 20.0% – 12.5%), and attention (73.7% – 40.0% – 62.5%).

**Neuropsychiatric manifestations in TSC vs NF1**

Table 3 reports the comparison of neuropsychiatric involvement between TSC and NF1.
| Neuropsychiatric features: comparison between NF1 and TSC subjects |
|---------------------------------------------------------------|
| **NF1 subjects**  | **TSC subjects**  | **U** | **Asymp. Sig. (2-sided)** |
| (n = 42) | (n = 42) |  | **p value** |
| **Age (year) mean ± SD** | 11.33 ± 4.25  | 11.36 ± 4.19  | 880.000 | 0.986 |
| **Range** | 4–20 | 4–19 |  |  |
| **Gender** | 19 (45.2)  | 19 (45.2)  | 0.000 | 1.000 |
| **Male** | 23 (54.8)  | 23 (54.8)  | 0.000 | 1.000 |
| **Female** |  |  |  |  |
| **TAND Features** |  |  |  |  |
| **Behavioural level** |  |  |  |  |
| **Anxiety** | 21 (50.0)  | 19 (45.2)  | 0.191 | 0.662 |
| **Depressed mood** | 9 (21.4)  | 6 (14.3)  | 0.730 | 0.393 |
| **Extreme shyness** | 7 (16.7)  | 8 (19.0)  | 0.081 | 0.776 |
| **Mood swings** | 11 (26.2)  | 10 (23.8)  | 0.063 | 0.801 |
| **Aggressive outbursts** | 8 (19.0)  | 17 (40.5)  | 4.613 | 0.032 |
| **Temper tantrums** | 16 (38.1)  | 23 (54.8)  | 2.345 | 0.126 |
| **Self-injury** | 1 (2.4)  | 5 (11.9)  | 2.872 | 0.090 |
| **Absent or delayed onset of language** | 6 (14.3)  | 17 (40.5)  | 7.244 | 0.007 |
| **Repetitive language** | 4 (9.5)  | 11 (26.2)  | 3.977 | 0.046 |
| **Poor eye contact** | 2 (4.8)  | 8 (19.0)  | 4.086 | 0.043 |
| **Difficult relationship with peers** | 6 (14.3)  | 12 (28.6)  | 2.545 | 0.111 |
| **Repetitive behaviors** | 3 (7.1)  | 15 (35.7)  | 10.182 | 0.001 |
| **Rigidity** | 11 (26.2)  | 13 (31.0)  | 0.0233 | 0.629 |
| **Overactivity/hyperactivity** | 16 (38.1)  | 17 (40.5)  | 0.050 | 0.823 |
| **Difficulty paying attention or concentrating** | 25 (59.5)  | 26 (61.9)  | 0.050 | 0.823 |
| **Restlessness** | 8 (19.0)  | 10 (23.8)  | 0.283 | 0.595 |
| **Impulsivity** | 22 (52.4)  | 23 (54.8)  | 0.048 | 0.827 |
| **Difficulties with eating** | 13 (31.0)  | 13 (31.0)  | 0.000 | 1.000 |
| **Sleep difficulties** | 12 (28.6)  | 13 (31.0)  | 0.057 | 0.811 |
| Scholastic level            | NF1 n = 42 | TSC n = 42 | U   | P value |
|-----------------------------|------------|------------|-----|---------|
| Reading                     | 14 (33.3)  | 21 (50.0)  | 2.400 | 0.301   |
| Writing                     | 19 (45.2)  | 23 (54.8)  | 0.781 | 0.677   |
| Spelling                    | 17 (40.5)  | 19 (45.2)  | 0.194 | 0.659   |
| Mathematics                 | 20 (47.6)  | 26 (61.9)  | 1.732 | 0.421   |
| Neuropsychological level    |            |            |      |         |
| Memory                      | 12 (28.6)  | 11 (26.2)  | 0.060 | 0.807   |
| Attention                   | 25 (59.5)  | 26 (61.9)  | 0.050 | 0.823   |
| Dual-tasking                | 16 (38.1)  | 24 (57.1)  | 3.055 | 0.081   |
| Visuo-spatial tasks         | 4 (9.5)    | 8 (19.0)   | 1.556 | 0.212   |
| Executive skills            | 16 (38.1)  | 21 (50.0)  | 1.208 | 0.272   |
| Getting disoriented         | 4 (9.5)    | 12 (28.6)  | 4.941 | 0.026   |
| Psychosocial level          |            |            |      |         |
| Low self-esteem             | 15 (35.7)  | 11 (26.2)  | 0.891 | 0.345   |
| Very high levels of stress in families | 14 (33.3) | 16 (38.1) | 0.207 | 0.649 |
| Very high levels of stress between parents | 8 (19.0) | 18 (42.9) | 5.570 | 0.018 |

Significant differences were obtained for aggressive outbursts ($p = 0.032$), absent or delayed onset of language ($p = 0.007$), repetitive language ($p = 0.046$), poor eye contact ($p = 0.043$), repetitive behaviors ($p = 0.001$), getting disoriented ($p = 0.026$), very high level of stress between parents ($p = 0.018$), with the TSC patients more frequently affected.

Anxiety, temper tantrums, rigidity, overactivity/hyperactivity, difficulty paying attention or concentrating and impulsivity, sleep difficulties, reading, writing, spelling and mathematics, attention, executive skills, low self-esteem, very high level of stress in families were very equally present in patients affected by TSC and NF1.

**Discussion**

TSC and NF1 are the most common genetic disorders with cutaneous and neurological involvement. They present many challenges in management due to their heterogeneous presentation and large inter and intrafamilial clinical variability. Although their genetic basis and phenotype are different, they are both tumor-prone...
disorders resulting from the dysregulation of components of the convergent RAS/MAPK and PI3K/AKT/mTOR pathways (27)(28)(29).

In both disorders the prevalence of neuropsychiatric problems is relevantly higher than in the general population and impact quality of life (23)(4). However, these issues are not always addressed adequately, as physicians are usually more concerned about life-threatening complications of both diseases. Moreover, neuropsychiatric evaluation is time-consuming and needs specialized staff. As a result, neuropsychiatric complications may remain underdiagnosed even in expert centers (26).

The TAND-Checklist was developed to provide healthcare professionals with a tool to easily screen neuropsychiatric involvement in patients with TSC. The checklist explores the frequency of a wide range of neuropsychiatric manifestations and the multiple dimensions of the involvement on different levels: behavioral, psychiatric, intellectual, academic, neuropsychological and psychosocial (24). As these aspects can be impaired also in NF1 patients, we hypothesized that the checklist could be useful for screening neuropsychiatric needs in this population as well.

The TAND Checklist showed a wide range of neuropsychiatric issues in our TSC cohort. More than half of the parents reported temper tantrums, difficulty in paying attention and concentrating, impulsivity, scholastic difficulties, attention and executive skills deficits in their children. This profile is in line with the results of TAND data from the large-scale international TOSCA study (30). The interesting aspect is the result of the study of TAND in the epilepsy subgroups. In the TSC cohort 69.0% of the patients had a history of epilepsy (38.1% were seizure free at the time of evaluation and the remaining 30.9% had active epilepsy with variable seizure frequency). We found a statistically significant correlation between epilepsy severity and TAND, except for anxiety, extreme shyness, mood swings, aggressive outbursts, temper tantrums, self-injury, poor eye contact, rigidity, overactivity/hyperactivity, difficult paying attention, restlessness, impulsivity, difficulties with eating, sleep difficulties, academic difficulties (spelling and mathematics) and neuropsychological problems (dual-tasking, visuo-spatial tasks, executive skills, getting disoriented). These last features that are highly reported also in patients with no history of epilepsy, may be considered associated with the disease itself and deserve a deeper consideration both in terms of diagnosis and care in all TSC affected individuals (30). As we expected, disease-related variables of epilepsy have a significant impact on depressed mood, absent or delayed onset of language, repetitive language and behavior, difficult relationship with peers, and specific neuropsychological domains. The severity of epilepsy, in particular with early onset and poorly controlled seizures, is strongly associated with cognitive impairment and ASD (31)(32)(33). On the other hand, TSC patients without epilepsy did not report any feature associated with ASD. Our findings are in line with the study recently published by Toldo et al. (34), which identified a major impact of early-onset epilepsy on ASD features of TAND in a group of 32 Italian children with TSC, and a higher risk of developing anxious and depressive disorders in individuals with a less severe neurological phenotype.

By administering the TAND-Checklist to an age- and gender-matched sample of patients with NF1, we observed difficulties in attention and concentration, impulsivity and anxiety in more than 50% of the patients. Temper tantrums, overactivity/hyperactivity, academic difficulties, executive skill deficits, low self-esteem and very high level of stress in families were reported in more than 30% of children and adolescents with NF1.
Attention problems and ADHD represent well-known behavioral problems in NF1 children as approximately one-third to one-half of children with NF1 fulfill the criteria for ADHD (12). In line with data from the literature, the TAND-Checklist found frequent ADHD-like features: difficulty in paying attention and concentrating in 59.5%, impulsivity in 52.4%, overactivity/hyperactivity in 38.1% and poor attention in 59.5%. These aspects do not show a clear correlation with the disease severity according to the modified version of Riccardi medical severity scale. Of note however, this scale does not include cognitive and behavioral characteristics more directly involved in general adaptive functioning in daily-life (35).

Moreover, regardless of having a comorbid diagnosis of ADHD, children with NF1 show several signs of executive dysfunction compared with typically developing children (36). Riva et al. (37) found that children with NF1 have specific executive deficits that have an impact on real-life situations. This data is confirmed by our findings from the TAND-checklist applied to NF1, which show the presence of poor executive skills in 38.1% of the patients with NF1.

With regard to emotional and behavioral problems, some studies have evaluated children and adolescents with NF1 through the parents’ compilation of Child Behavior Checklist (CBCL) questionnaires. Rietman et al. (20) showed that on 183 subjects 32% fell in the clinical range, considering Total scores. Graf et al. (21) identified problems predominantly in the internalizing domain of anxiety, depression, social withdrawal and somatic complaints. Studies investigating anxiety in children and adolescents with NF1 have found a higher predisposition to developing an anxiety disorder, but have relied on relatively small sample sizes (38). In our cohort of NF1 patients 50.0% were reported to have anxiety symptoms, and no statistically significant differences were noted in the three severity subgroups. Only 15 patients with NF1 had received a formal psychiatric assessment, and 7/15 (46.6%) received a diagnosis of ADHD and 5/15 (33.3%) had been diagnosed with anxious or mood disorders. It is therefore possible that the TAND-Checklist is useful to identify more NF1 children with dysfunctional behavioral or psychological problems who may benefit from a full behavioral and neuropsychological assessment.

Regarding academic performances, children and adolescents with NF1 commonly perform more poorly at school than how their intellectual abilities would predict (14). In our sample scholastic difficulties were reported in all domains (reading, writing, spelling and mathematics). Taken together, 41.7% had one or a combination of deficits. Almost all of them received personalized plans and compensatory measures at school, and 21.4% were formally assessed and classified as Specific Learning Disorder.

Taken together, the results of the TAND-Checklist applied to NF1 are congruent with the medical literature, are useful to outline a profile of the neuropsychiatric involvement in NF1 and to collect patients’ needs.

In addition, it is noteworthy that parents showed a great interest in this screening tool, asked pertinent questions to the examiner, collaborated with enthusiasm and 21.4% declared the need for a supplementary in-depth analysis of their children’s neuropsychiatric problems, mostly at the behavioral level.

Lastly, we compared the frequencies of the neuropsychiatric manifestations resulting from the checklist in the two conditions. Individuals with TSC were reported to have a greater neuropsychiatric involvement in all the investigated levels.
Cognitive assessment was performed in all TSC and NF1 participants and, as expected, patients with TSC performed lower than patients with NF1. Indeed, the mean IQ in the NF1 cohort was 94 with only 9.5% having mild ID, whereas the mean IQ in the TSC cohort was 74 with 37.7% having various degrees of ID. We found aggressive outburst to be statistically significantly higher in the TSC group. Aggression is common in TSC and is usually associated with stereotyped and repetitive behaviors, low mood, hyperactivity, impulsivity and repetitive use of language, in subjects with intellectual disabilities (39).

We demonstrated statistically significant differences also in the behavioral manifestations of ASD, which are more common in the TSC patients: absent or delayed onset of language, repetitive language, poor eye contact and repetitive behaviors.

It is known that ASD in TSC can be present in 40–50% of the patients (8)(40) being one of the most characteristic disease trait. On the other hand, prevalence rates of clinical ASD symptoms in children with NF1, based on screening instruments, are between 13–29% (41)(42) with a statistically significant comorbidity with symptoms of ADHD. A recent study by Eijk et al. (19) used standardized diagnostic methods and found a prevalence of clinical ASD of 10.9%. No one in our NF1 cohort had formal diagnosis of ASD, and the features commonly associated with ASD (such as absent or delayed onset of language, repetitive language, poor eye contact, difficulties in relationship with peers and repetitive behaviors) were reported in less than 15% of the patients.

Individuals with NF1 were recognized to have more difficulties, though non statistically significant, in anxiety, depressed mood and low self-esteem. It can be difficult to investigate these aspects in TSC, given the high rate of ID in this population, and anxiety or depression symptoms can manifest with behavioral changes over time (7). On the other hand, patients with NF1 have a higher mean IQ and are more aware of their illness.

It is noteworthy that the two samples, despite the differences in IQ levels, had almost identical high rates of ADHD-like symptomatology (overactivity/hyperactivity, difficulty paying attention or concentrating, impulsivity, poor attention and poor executive skills) and of scholastic difficulties (reading, writing, spelling and mathematics). All these features are confirmed to be frequently associated with the disease and deserve a deeper consideration both in terms of diagnosis and care in all TSC and NF1 children.

Conclusions

This study adds data about the use of the TAND checklist in the evaluation of patients with TSC and explores the use of this tool in patients with NF1 for the first time.

Our experience confirms the previously reported findings in TSC, and it suggests the possibility to extend the use of this tool to screen for neuropsychiatric involvement in other neurological diseases with complex needs.

The TAND checklist is acceptable and feasible to complete in a clinic setting, and is able to detect the complexity of neuropsychiatric involvement in NF1, as shown by our results. It can be integrated into the routine medical appointments of individuals with NF1 and can produce interpretable and actionable results. The subset of patients who reported a high incidence of issues and is therefore considered at risk for certain neuropsychiatric disorders can be referred for further appropriate assessment and intervention. Furthermore,
the checklist can be easily re-administered during follow-up in order to detect the behavioral and psychological changes over time and the efficacy of therapeutic intervention.

**Methods**

The authorized Italian version of the TAND-Checklist was administered to 42 consecutively enrolled TSC patients (23 Females and 19 Males, mean age 11.36 ± 4.19 years), followed at the Tuberous Sclerosis Clinic, ASST Santi Paolo e Carlo, Milan, and to 42 NF1 patients matched for age and gender (23 Females and 19 Males, mean age 11.33 ± 4.25 years) from the Neurofibromatosis Clinic, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

All the 84 patients, aged from 4 to 20 years, met the diagnostic clinical criteria for TSC and NF1 and underwent the specific genetic tests. Brain MRIs and clinical/instrumental disease-specific follow-ups were performed in all individuals. Informed consent was obtained, and this study was approved by the ethics committee of our Institutions.

The Italian version of the TAND-Checklist was administered by the same physician (F.C.) to the patients’ parents, during scheduled visits of follow-up assessments or through a telephone interview.

We used the TAND Checklist exactly as is, and only replaced the term “TSC” with “NF1” when needed during the administration. To avoid possible significant discordance between the ratings given by the caregivers and the adolescents and also to have a homogeneous observer/witness ratio for all age groups, we interviewed exclusively the parents. The parent who completed the questionnaire was the caregiver usually involved in the patient’s daily management.

We collected data about cognitive functioning and clinical, neurophysiological and brain imaging characteristics. General development and intelligence quotients were respectively evaluated using the Griffiths’ Scales of Infant Development, GMDS-ER and the Wechsler Scales of Intelligence, according to the patients’ age.

Table 4a and 4b report the clinical characteristics of the sample. To evaluate a possible correlation between the TAND-Checklist and the clinical expression of the two diseases, each cohort was divided into subgroups based on the phenotype severity.
Table 4
a Clinical characteristics of the TSC Cohort

|                                | TSC patients (n = 42) |
|--------------------------------|-----------------------|
| Age (year) mean ± SD           | 11.36 ± 4.19          |
| Range                          | 4–19                  |
| Gender                         |                       |
| Male                           | 19 (45.2%)            |
| Female                         | 23 (54.8%)            |
| Diagnostic criteria met for TSC| 42 (100%)             |
| Tubers (brain MRI)             | 37 (88.1%)            |
| Never had epilepsy             | 13 (31.0%)            |
| Well controlled epilepsy (seizure free) | 16 (38.1%) |
| Active epilepsy                | 13 (31.0%)            |
| One or more seizures/day       | 3 (23.1%)             |
| One or more seizures/week      | 8 (61.5%)             |
| Sporadic seizures              | 2 (15.4%)             |
| Antiepileptic treatment        | 28 (66.7%)            |
| Monotherapy                    | 11 (39.3%)            |
| Polytherapy                    | 17 (60.7%)            |
| Neurosurgical treatment for epilepsy | 3 (7.1%)  |
| Subependymal giant cell astrocytoma (SEGA) | 10 (23.8%) |
| Neurosurgical treatment for SEGA | 2 (20.0%)            |
| SEGA treated with Everolimus   | 6 (60.0%)             |
| Stable SEGA on brain MRI       | 2 (20.0%)             |
| Received IQ assessment         | 42 (100%)             |
| Median IQ ± SD Range           | 74.48 ± 28.05         |
| Range                          | 20–134                |
| Normal IQ                      | 17 (40.5%)            |
| BIF                            | 10 (23.8%)            |

BIF Borderline Intellectual Functioning; ID Intellectual Disability; IEP Individualized Educational Plan; SLD Specific Learning Disorder
| Condition                                      | TSC patients (n = 42) |
|-----------------------------------------------|-----------------------|
| Mild ID                                       | 4 (9.5%)              |
| Moderate ID                                   | 8 (19.0%)             |
| Severe/profound ID                            | 3 (7.1%)              |
| Received formal psychiatric assessment        | 12 (28.6%)            |
| ASD                                           | 4 (33.3%)             |
| ADHD                                          | 6 (50.0%)             |
| Anxious/Depressed Disorder                    | 2 (16.6%)             |
| Additional support in school (i.e. IEP)       | 28 (66.7%)            |
| SLD                                           | 5 (11.9%)             |
| Low self-esteem (per parents’ report)         | 11 (26.2%)            |
| Very high levels of stress in families         | 16 (38.1%)            |
| Very high levels of stress between parents    | 18 (42.9%)            |

BIF Borderline Intellectual Functioning; ID Intellectual Disability; IEP Individualized Educational Plan; SLD Specific Learning Disorder
### Table 4

**b: Clinical characteristics of the NF1 Cohort**

| NF1 patients (n = 42) |
|-----------------------|
|                       |
| **Age (year) mean ± SD** |
| **Range** |
| 11.33 ± 4.25 |
| 4–20 |
|                       |
| **n (%)** |
| 19 (45.2%) |
| 23 (54.8%) |
|                       |
| **Gender** |
| Male |
| Female |
| 11 (78.6%) |
| 2 (14.3%) |
| 1 (7.1%) |
|                       |
| **Other CNS tumors** |
| 5 (11.9%) |
|                       |
| **Neurosurgical treatment** |
| 2 (40.0%) |
|                       |
| **Chemotherapy** |
| 1 (20.0%) |
|                       |
| **Plexiform neurofibromas (NF)** |
| 12 (28.6%) |
|                       |
| **Plexiform NF treated with surgery** |
| 2 (16.6%) |
|                       |
| **Received IQ assessment** |
| 42 (100%) |
|                       |
| **Median IQ ± SD** |
| **Range** |
| 94.32 ± 14.89 |
| 59–113 |
|                       |
| **Normal IQ** |
| 33 (78.6%) |
|                       |
| **BIF** |
| 5 (11.9%) |
|                       |
| **Mild ID** |
| 4 (9.5%) |
|                       |
| **Moderate/severe ID** |
| 0 (0.0%) |
|                       |
| **Received formal psychiatric assessment** |
| 15 (35.7%) |
|                       |
| **ASD** |
| 0 (0.0%) |
|                       |
| **ADHD** |
| 7 (46.6%) |
|                       |
| **Anxious/Depressed Disorder** |
| 5 (33.3%) |

BIF Borderline Intellectual Functioning; ID Intellectual Disability; IEP Individualized Educational Plan; SLD Specific Learning Disorder
| Additional support in school (i.e. IEP) | 21 | (50.0%) |
| SLD | 9 | (21.4%) |
| Low self-esteem (per parents’ report) | 15 | (35.7%) |
| Very high levels of stress in families | 14 | (33.3%) |
| Very high levels of stress between parents | 8 | (19.0%) |

BIF Borderline Intellectual Functioning; ID Intellectual Disability; IEP Individualized Educational Plan; SLD Specific Learning Disorder

To date, there is no proposal for classification of patients based on disease severity in TSC. Since one of the major burdens of TSC is the presence of epilepsy, we divided the cohort according to: no history of epilepsy, epilepsy that was not active at the time of the evaluation (namely, patients who had been seizure free for the last 6 months), and active epilepsy (epilepsy with variable seizure frequency).

We used a modified version (43) of the Riccardi severity scale (44) and divided the NF1 cohort into: Minimal NF1 (patient has no manifestations that compromise health, but has NF1 features such as CAL macules and freckling only), Mild NF1 (minor medical complications such as mild hypertension, asymptomatic plexiform neurofibroma, or optic glioma), Moderate NF1 (complications that significantly compromise health with orthopaedic complications requiring bracing or surgery, large or symptomatic plexiform and moderate pain), and Severe NF1 (medical history of intractable seizures, severe chronic pain, visual impairment, inoperable tumors, and malignancies). Due to small group size, the moderate and severe subgroups were merged.

**Statistical analysis**

Data were analyzed using the Statistical Package for the Social Sciences (SPSS 25 IBM, Chicago, IL, U.S.A.) for Windows.

We used means ± standard deviation (SD) for quantitative variables and absolute counts and frequencies for qualitative variables.

The normality of the distributions of the quantitative variables was verified by applying the Shapiro-Wilk test.

Descriptive analysis of the demographic and clinical characteristics of the patients with NF1 and TSC was performed both on the whole cohort and by stratifying patients according to severity scale. We performed chi-square test for categorized variables and not normally distributed variables, otherwise the Mann-Whitney U test (two groups). We considered a two-tailed p value of 0.05 or less statistically significant.

**Abbreviations**

ADHD
Attention Deficit Hyperactivity Disorder
ASD
Autistic Spectrum Disorder
CAL
café-au-lait
CBCL
Child Behavior Checklist
ID
Intellectual Disability
IQ
Intelligence Quotient
NF1
Neurofibromatosis type 1
SEGAs
Subependymal Giant cell Astrocytomas
SLD
Specific Learning Disorders
TAND
Tuberous Sclerosis Associated Neuropsychiatric Disorders
TOSCA
Tuberous Sclerosis registry to increase disease Awareness
TSC
Tuberous Sclerosis Complex

References

1. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet. 2007;44(2):81–8.

2. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):243–54.

3. Korf BR, Bebin EM. Neurocutaneous Disorders in Children. Pediatr Rev [Internet]. 2017;38(3):119–28. Available from: http://pedsinreview.aappublications.org/lookup/doi/10.1542/pir.2015-0118

4. Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol. 2017;59(11):1112–6.

5. Canevini MP, Kotulska-Jozwiak K, Curatolo P, La Briola F, Peron A, Słowińska M, et al. Current concepts on epilepsy management in tuberous sclerosis complex. Am J Med Genet Part C Semin Med Genet [Internet]. 2018;(August):1–10. Available from: http://doi.wiley.com/10.1002/ajmg.c.31652

6. Kingswood JC, D’Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. Tuberous Sclerosis registry to increase disease Awareness (TOSCA) - Baseline data on 2093 patients. Orphanet J Rare Dis [Internet]. 2017;12(1):1–13. Available from: http://dx.doi.org/10.1186/s13023-016-0553-5
7. de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Am J Med Genet Part C Semin Med Genet [Internet]. 2018;(May):1–12. Available from: http://doi.wiley.com/10.1002/ajmg.c.31637

8. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol [Internet]. 2015;14(7):733–45. Available from: http://dx.doi.org/10.1016/S1474-4422(15)00069-1

9. De Vries PJ, Watson P. Attention deficits in tuberous sclerosis complex (TSC): Rethinking the pathways to the endstate. J Intellect Disabil Res. 2008;52(4):348–57.

10. Lehtonen A, Garg S, Roberts SA, Trump D, Evans DG, Green J, et al. Cognition in children with neurofibromatosis type 1: data from a population-based study. Dev Med Child Neurol. 2015 Jul;57(7):645–51.

11. Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera Gomez PM. Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr [Internet]. 2017;5(October). Available from: http://journal.frontiersin.org/article/10.3389/fped.2017.00227/full

12. Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: Cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2013;55(2):111–25.

13. Bulgheroni S, Taddei M, Saletti V, Esposito S, Micheli R, Riva D. Visuoperceptual Impairment in Children with NF1: From Early Visual Processing to Procedural Strategies. Behav Neurol. 2019;2019:7146168.

14. Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006 Dec;48(12):973–7.

15. Pride NA, Payne JM, North KN. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol. 2012;37(7):590–600.

16. Kayl AE, Moore BD. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev. 2000;6(2):117–24.

17. Levine TM, Materek A, Abel J, O’Donnell M, Cutting LE. Cognitive Profile of Neurofibromatosis Type 1. Semin Pediatr Neurol [Internet]. 2006 Mar 1 [cited 2018 Oct 10];13(1):8–20. Available from: https://www.sciencedirect.com/science/article/pii/S1071909106000106?via%3Dihub

18. Lidzba K, Granstrom S, Lindenau J, Mautner V-F. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012 Oct;54(10):892–7.

19. Eijk S, Mous SE, Dieleman GC, Dierckx B, Rietman AB, de Nijs PFA, et al. Autism Spectrum Disorder in an Unselected Cohort of Children with Neurofibromatosis Type 1 (NF1). J Autism Dev Disord [Internet]. 2018;48(7):2278–85. Available from: https://doi.org/10.1007/s10803-018-3478-0

20. Rietman AB, van der Vaart T, Plasschaert E, Nicholson BA, Oostenbrink R, Krab LC, et al. Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):319–28.

21. Graf A, Landolt MA, Mori AC, Boltshauser E. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr [Internet]. 2006 Sep 1;149(3):348–53. Available from: https://doi.org/10.1016/j.jpeds.2006.04.025
22. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):255–65.

23. De Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND checklist. Pediatr Neurol [Internet]. 2015;52(1):25–35. Available from: http://dx.doi.org/10.1016/j.pediatrneurol.2014.10.004

24. Leclezio L, Jansen A, Whittemore VH, De Vries PJ. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol [Internet]. 2015;52(1):16–24. Available from: http://dx.doi.org/10.1016/j.pediatrneurol.2014.10.006

25. Wiener L, Battles H, Bedoya SZ, Baldwin A, Widemann BC, Pao M. Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1). J Genet Couns. 2018;27(1):115–23.

26. Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR; COUNCIL ON GENETICS; AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics. 2019;143(5).

27. Gutmann DH. Parallels between tuberous sclerosis complex and neurofibromatosis 1: Common threads in the same tapestry. Semin Pediatr Neurol [Internet]. 1998;5(4):276–86. Available from: http://www.sciencedirect.com/science/article/pii/S1071909198800065

28. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011 Jun;36(6):320–8.

29. Borrie SC, Brems H, Legius E, Bagni C. Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways. Annu Rev Genomics Hum Genet. 2017 Aug;18:115–42.

30. Vries PJ De, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. 2018;1–13.

31. van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol [Internet]. 2013;55(2):146–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23205844%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4071146

32. Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Maréchal K, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med [Internet]. 2015 Aug 1 [cited 2018 Oct 10];45(11):2321–31. Available from: http://www.journals.cambridge.org/abstract_S0033291715000264

33. Moavero R, Napolitano A, Cusmai R, Vigevano F, Figà-Talamanca L, Calbi G, et al. White matter disruption is associated with persistent seizures in tuberous sclerosis complex. Epilepsy Behav [Internet]. 2016 Jul 1;60:63–7. Available from: https://doi.org/10.1016/j.yebeh.2016.04.026

34. Toldo I, Brasson V, Miscioscia M, Pelizza MF, Manara R, Sartori S, et al. Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study. Dev Med Child Neurol. 2019 Feb;61(2):168–73.

35. Eby NS, Griffith JL, Gutmann DH, Morris SM. Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Dev Med Child Neurol. 2019 Aug;61(8):972–8.
36. Payne JM, Arnold SS, Pride NA, North KN. Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1? Dev Med Child Neurol. 2012 Oct;54(10):898–904.

37. Riva D, Vago C, Erbetta A, Saletti V, Esposito S, Micheli R, et al. The Key Search Subtest of the Behavioural Assessment of the Dysexecutive Syndrome in Children (BADS-C) Instrument Reveals Impaired Planning Without External Constraints in Children With Neurofibromatosis Type 1. J Child Neurol. 2017 Mar;32(4):387–96.

38. Pasini A, Lo-Castro A, Di Carlo L, Pitzianti M, Siracusano M, Rosa C, et al. Detecting anxiety symptoms in children and youths with neurofibromatosis type I. Am J Med Genet Part B Neuropsychiatr Genet. 2012;159 B(7):869–73.

39. Eden KE, De Vries PJ, Moss J, Richards C, Oliver C. Self-injury and aggression in tuberous sclerosis complex: Cross syndrome comparison and associated risk markers. J Neurodev Disord. 2014;6(1):1–11.

40. Vignoli A, La Briola F, Peron A, Turner K, Vannicola C, Saccani M, et al. Autism spectrum disorder in tuberous sclerosis complex: Searching for risk markers. Orphanet J Rare Dis [Internet]. 2015;10(1):1–9. Available from: http://dx.doi.org/10.1186/s13023-015-0371-1

41. Walsh KS, Vélez JI, Kardel PG, Imas DM, Muenke M, Packer RJ, et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol. 2012;55(2):131–8.

42. Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans D, et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: Evidence from a population-based study. Dev Med Child Neurol. 2013;

43. Noll RB, Reiter-Purtill J, Moore BD, Schorry EK, Lovell AM, Vannatta K, et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A. 2007 Oct;143A(19):2261–73.

44. Riccardi, Vincent and Smirniotopoulos J. Neurofibromatosis, phenotype, natural history, and pathogenesis. J Neuropathol Exp Neurol. 1992;51(6).

**Ethics Declarations**

**Ethics approval and consent to participate**

The study was approved by the Medical Ethical Committees of the participating centers. All patients and/or parents gave informed consent to participate in this study.

**Consent for publication**

Not applicable. No individual person’s data in any form (including individual details, images or videos) are included in the study.

**Funding**

Not applicable.
Availability of data and materials

All data generated or analyzed during this study are included in this published article and its additional files.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

The authors thank all patients for taking part of the study. In addition, we kindly acknowledge Prof. P.J. de Vries for his help with the study.

Authors’ contributions

Conceptualization of the ideas, formulation and evolution of research goals and aims, and writing the article: CV, VS, AP and AV. Provision of study materials and patients’ management: CV, FLB, SB, MT. Statistical analysis: KT. Revision of the article: MPC. All authors read and approved the final manuscript.